- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05027698
Post-Market Clinical Investigation of the FemoSeal™ VCS: A Prospective, Multi-Center Observational European Study (FEMOSEAL CLOSE)
FEMOSEAL CLOSE - Post-Market Clinical Investigation of the FemoSeal™ VCS: A Prospective, Multi-Center Observational European Study
Study Overview
Status
Detailed Description
The proposed Post-Market Clinical Follow-up study is a Prospective, Multi-Center, Observational Study, aiming to further demonstrate the safety and effectiveness of the FemoSealTM VCS in achieving hemostasis of common femoral artery (CFA) access site in real-world subjects undergoing percutaneous endovascular procedures. 230 patients will be enrolled at up to 6 European sites. Follow-ups are scheduled at 30 days (±7 days) by hospital visit or telephone call.
The sponsor shall provide training and the necessary guidelines to assist each investigation site on the data collection in the eCRF. Each site is responsible to report the available data requested by the CIP. In order to ensure data quality, validation & consistency, edit checks will be designed during database development. Data Management team and the study monitors will be responsible to review the data and raise queries in the eCRF. Data cleaning will be done in regular intervals specified in Data Monitoring Plan. The final clean standardised datasets will be available prior to database lock for data analysis. An audit trail logging all data entered and edited is available within the EDC system. All source documents are maintained in the hospital files ready for inspection by the Sponsor and regulatory authorities upon request. The Sponsor will inform the investigator of the time period for retaining these records as per applicable regulatory requirements.
The study will be monitored at all stages of its development by study monitors appointed by the sponsor. Study monitors are designated as Sponsor representatives and are assigned to oversee the conduct and progress of the study at each site in accordance with the Monitoring Plan established for this clinical investigation.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Dendermonde, Belgium, 9200
- AZ Sint Blasius
-
-
-
-
-
Paris, France, 75014
- Hôpital Paris St Joseph, Vascular and endovascular surgical center
-
-
-
-
Baden-Württemberg
-
Bad Krozingen, Baden-Württemberg, Germany, 79189
- Universitäts-Herzzentrum Freiburg Bad Krozingen, Department of Cardiology and Angiology Department
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subject is ≥ 18 years old
- Subject is willing and able to complete the follow-up requirements
- Subject has the mental capacity (i.e. does not require the use of a Legally Authorized Representative) to sign the study Informed Consent Form (ICF)
- Patient undergoing diagnostic or interventional endovascular procedure compatible with the use of FemoSeal™ VCS
- Puncture site located at the CFA (i.e. between the inferior epigastric artery and the bifurcation of the superficial and profunda femoral arteries)
- FemoSeal™ VCS deployed as per instruction for use by a trained operator on arteriotomy where sheaths or devices of ≤7F were used, following a femoral artery angiogram
Exclusion Criteria:
- Any contraindication to the endovascular treatment and/or FemoSeal™ VCS use as per IFU
- Use of the FemoSeal™ VCS on puncture sites other than CFA
- Repuncture of the CFA within 90 days at the same access site
Enrollment of a patient with the contralateral CFA puncture, when a prior target limb access site has been selected for the study and a FemoSealTM deployment has been performed.
Additionally, patients will be examined intraoperatively and excluded from the study if any of the following were observed by the treating physician:
- Lumen diameter of CFA < 5 mm
- Stenosis and/or significant plaque present in the vicinity of the CFA puncture site
- Arterial puncture is at, or distal to, the femoral artery bifurcation
- Anomalous branches or vessel abnormalities present in the vicinity of the CFA puncture site
- Use of > 7F primary introducer sheaths or devices
- Multiple femoral punctures
- Known or suspected posterior femoral wall puncture
- Any condition that would make use of the closure device inappropriate (as per investigators' discretion)
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effectiveness endpoint: Successful puncture site haemostasis
Time Frame: within 6 hours post procedure
|
Cessation of arterial bleeding (excluding oozing) achieved in the CathLab in subjects not requiring any adjunctive intervention at the access site, including (but not limited to) sterile wound dressing and/or manual compression.
|
within 6 hours post procedure
|
Safety endpoint: Freedom from major complications
Time Frame: within 6 hours post procedure
|
Freedom from major complications of the access site limb
|
within 6 hours post procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from any minor complications at the target limb access site.
Time Frame: within 6 hours post procedure
|
Minor complications are defined as:
|
within 6 hours post procedure
|
Freedom from any major and minor complications at the target limb access site.
Time Frame: within 6 hours to 30 days post-procedure
|
within 6 hours to 30 days post-procedure
|
|
Time to hemostasis (TTH)
Time Frame: up to 1 day
|
Defined as time between the removal of the procedural sheath up to first observed arterial bleeding cessation (excluding oozing at access site) in subjects not requiring adjunctive intervention in the cathlab.
|
up to 1 day
|
Time to ambulation (TTA)
Time Frame: up to 30 days
|
Defined as the time between the procedural sheath removal and the moment when the patient is able to ambulate, i.e. autonomously stand up from the bed and walk without recurrent bleeding.
|
up to 30 days
|
Length of stay in hospital
Time Frame: up to 30 days
|
i. e. the time between the procedural sheath removal and the moment when the patient is discharged from the hospital
|
up to 30 days
|
Quality of Life assessment
Time Frame: at baseline, discharge , and 30 days
|
Quality of Life assessed as per EuroQl five-dimensional (EQ-5D) questionnaire: The first part of the questionnaire contain descriptive questions on 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression, each with 5 levels of responses. The second part of the questionnaire contains a standard vertical 20-cm visual analog scale that is calibrated from 'the worst health you can imagine' (scored 0) at its base to 'the best health you can imagine' (scored 100) at its apex. |
at baseline, discharge , and 30 days
|
FemoSeal™ VCS usability
Time Frame: up to 1 day
|
Accessed by questionnaire, including, but not limited to the following items (usefulness; ease of use; ease of learning; satisfaction and intention to use) completed by operators.
|
up to 1 day
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- T138E4
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Vascular Disease
-
C. R. BardCromsourceCompletedVascular Diseases, PeripheralGermany, Poland
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingPeripheral Vascular Disease | Peripheral Artery DiseaseUnited States
-
University of MichiganTerminatedPeripheral Vascular Disease | Peripheral Artery DiseaseUnited States
-
SensomeRecruitingPeripheral Vascular DiseaseBelgium
-
Biotronik, Inc.CompletedPeripheral Vascular Disease | Peripheral Artery DiseaseCanada, United States
-
Biotronik AGBiotronik, Inc.UnknownPeripheral Vascular Disease | Peripheral Artery DiseaseGermany, Belgium, Austria, Switzerland
-
Baylor UniversityNational Institute on Aging (NIA)RecruitingArterial Occlusive Diseases | Peripheral Arterial Disease | Atherosclerosis | Vascular Diseases, PeripheralUnited States
-
Acotec Scientific Co., LtdRecruitingPeripheral Arterial Disease (PAD) | Peripheral Vascular Disease (PVD)China